000			01960nam a2200493 i 4500
005			20250919090741.0
006			m eo d
007			cr cn |||m|||a
008			170322s2013 enka ob 001 0 eng d
020			_z9781780843292 (print)
020			_a9781780843285 (ePub)
020			_a9781780843278 (eISBN)
040			_dUKM _erda
090			_aebook PHCTM
245	0	0	_aMonoclonal antibodies targeting EGFR/HER2 and clinical outcomes in cancer treatment / _ceditor, Jan B. Vermorken.
264		1	_aLondon, England : _bFuture Medicine Ltd, _c2013.
300			_a1 electronic text (107 pages) : _bcolor illustrations, digital file.
336			_atext _2rdacontent
337			_acomputer _2radmedia
338			_aonline resource _2rdacarrier
490	1		_aThe Future Science Group eBook collection, _x2047-332X
504			_aIncludes bibliographical references and index.
506			_aRestricted to subscribers or individual electronic text purchasers.
530			_aAlso available in print.
538			_aSystem requirements: Adobe Acrobat Reader.
538			_aMode of access: World Wide Web.
588			_aTitle from PDF title page (Future Medicine eBooks Web site, viewed June 28, 2013).
650	1	2	_aNeoplasms _xDrug therapy
650	1	2	_aReceptor, Epidermal Growth Factor.
650	1	2	_aReceptor, erbB-2
650	1	2	_aAntibodies, Monoclonal _xTherapeutic use.
655		0	_aElectronic books.
700	1		_aVermorken, Jan B., _eeditor.
710	2		_aFuture Medicine Ltd.
776	0	8	_iPrint version: _z9781780843292
830		0	_aFuture Science Group eBook collection, _x2047-332X.
856	4	0	_uhttps://doi.org/10.2217/9781780843278
856	4	0	_uhttps://doi-org.eresourcesptsl.ukm.remotexs.co/10.2217/9781780843278
907			_a.b16452525 _b2023-06-27 _c2019-11-12
942			_n0 _kebook PHCTM
914			_avtls003619756
998			_ah _b2017-09-03 _cm _dz _feng _genk _y0 _z.b16452525
999			_c618403 _d618403